Abstract
In vitro-transcribed, messenger RNA-based infectious disease vaccines have the potential to successfully address many of the weaknesses of traditional vaccine platforms, such as the lack of potency and/or durability of vaccine protection, time-consuming, and expensive manufacturing, and, in some cases, safety issues. This optimism is fueled by a great deal of impressive recent data demonstrating that mRNA vaccines have many of the attributes that are necessary for a viable new vaccine class for human use. This review briefly describes mRNA vaccine types, discusses the most relevant and recent publications on infectious disease mRNA vaccines, and highlights the hurdles that need to be overcome to bring this promising novel vaccine modality to the clinic.
Keywords
- mRNA
- SAM
- LNP
- Clinical trials
- Infectious diseases
- Vaccines
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abrams MT et al (2010) Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 18:171–180. https://doi.org/10.1038/mt.2009.208
Akinc A, Thomas M, Klibanov AM, Langer R (2005) Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7:657–663. https://doi.org/10.1002/jgm.696
Alberer M et al (2017) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390(10101):1511–1520. https://doi.org/10.1016/S0140-6736(17)31665-3
Allard SD et al (2012) A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol 142:252–268. https://doi.org/10.1016/j.clim.2011.10.010
An Y et al (2013) Comparative glycomics analysis of influenza Hemagglutinin (H5N1) produced in vaccine relevant cell platforms. J Proteome Res 12:3707–3720. https://doi.org/10.1021/pr400329k
Andries O et al (2015) N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release 217:337–344. https://doi.org/10.1016/j.jconrel.2015.08.051
Asrani KH et al (2018) Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol 15:756–762. https://doi.org/10.1080/15476286.2018.1450054
Awasthi S et al (2019) Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol 4(39):eaaw7083. https://doi.org/10.1126/sciimmunol.aaw7083
Bahl K et al (2017) Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 25:1316–1327. https://doi.org/10.1016/j.ymthe.2017.03.035
Baiersdörfer M et al (2019) A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids 15:26–35. https://doi.org/10.1016/j.omtn.2019.02.018
Balazs DA, Godbey W (2011) Liposomes for use in gene delivery. J Drug Deliv 2011:326–497. https://doi.org/10.1155/2011/326497
Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME (2013) New vaccines for neglected parasitic diseases and dengue. Transl Res 162:144–155. https://doi.org/10.1016/j.trsl.2013.03.006
Beeson J G et al (2019) Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Sci Transl Med 11(474):eaau1458. https://doi.org/10.1126/scitranslmed.aau1458
Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951. https://doi.org/10.1038/nbt.3330
Bloom DE, Black S, Rappuoli R (2017) Emerging infectious diseases: a proactive approach. Proc Natl Acad Sci 114:4055–4059. https://doi.org/10.1073/pnas.1701410114
Bogers WM et al (2015) Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 211:947–955. https://doi.org/10.1093/infdis/jiu522
Brazzoli M et al (2016) Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol 90:332–344. https://doi.org/10.1128/JVI.01786-15
Brewer TF (2000) Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31(Suppl 3):S64–S67. https://doi.org/10.1086/314072
Brito LA et al (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 22:2118–2129. https://doi.org/10.1038/mt.2014.133
Bugeon S et al (2017) Direct and efficient transfection of mouse neural stem cells and mature neurons by in vivo mRNA electroporation. Development 144:3968–3977. https://doi.org/10.1242/dev.151381
Chahal JS et al (2016) Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci 113:E4133–E4142. https://doi.org/10.1073/pnas.1600299113
Chahal JS et al (2017) An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep 7:252. https://doi.org/10.1038/s41598-017-00193-w
Conry RM et al (1995) Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55:1397–1400
Cu Y et al (2013) Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ. Vaccines 1:367–383. https://doi.org/10.3390/vaccines1030367
Cullis PR, Hope MJ (2017) Lipid nanoparticle systems for enabling gene therapies. Mol Ther 25:1467–1475. https://doi.org/10.1016/j.ymthe.2017.03.013
de Jong W et al (2019) iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials 20:361. https://doi.org/10.1186/s13063-019-3409-1
Demoulins T et al (2016) Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine 12:711–722. https://doi.org/10.1016/j.nano.2015.11.001
Dezsi L et al (2014) Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. J Control Release 195:2–10. https://doi.org/10.1016/j.jconrel.2014.08.009
Dowling W et al (2007) Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J Virol 81:1821–1837. https://doi.org/10.1128/JVI.02098-06
Duthie MS et al (2018) Heterologous immunization with defined RNA and subunit vaccines enhances T Cell responses that protect against Leishmania donovani. Front Immunol 9:2420. https://doi.org/10.3389/fimmu.2018.02420
Erasmus JH et al (2018) A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika. Mol Ther 26:2507–2522. https://doi.org/10.1016/j.ymthe.2018.07.010
Feldman RA et al (2019) mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37:3326–3334. https://doi.org/10.1016/j.vaccine.2019.04.074
Fotin-Mleczek M et al (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34:1–15. https://doi.org/10.1097/CJI.0b013e3181f7dbe8
Gandhi RT et al (2016) Immunization of HIV-1-Infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: results of a randomized, placebo-controlled clinical trial. J Acquir Immune Defic Syndr 71:246–253. https://doi.org/10.1097/QAI.0000000000000852
Garcia AB et al (2018) Neutralization of the plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat Commun 9(1):1–13. https://doi.org/10.1038/s41467-018-05041-7
Gay CL et al (2018) Immunogenicity of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. AIDS Res Hum Retroviruses 34:111–122. https://doi.org/10.1089/aid.2017.0071
Gilleron J et al (2013) Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 31:638–646. https://doi.org/10.1038/nbt.2612
Guardo AC et al (2017) Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). AIDS 31:321–332. https://doi.org/10.1097/QAD.0000000000001276
Hajj KA, Whitehead KA (2017) Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater 2(10):1–17. https://doi.org/10.1038/natrevmats.2017.56
Halasa NB, Gerber MA, Chen Q, Wright PF, Edwards KM (2008) Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis 197:1448–1454. https://doi.org/10.1086/587643
Hassett KJ et al (2019) Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids 15:1–11. https://doi.org/10.1016/j.omtn.2019.01.013
Hekele A et al (2013) Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2:e52. https://doi.org/10.1038/emi.2013.54
Henao-Restrepo AM et al (2017) Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial. Lancet 389:505–518. https://doi.org/10.1016/S0140-6736(16)32621-6
Henry C, Palm AE, Krammer F, Wilson PC (2018) From original antigenic sin to the universal influenza virus vaccine. Trends Immunol 39:70–79. https://doi.org/10.1016/j.it.2017.08.003
Hicks DJ, Fooks AR, Johnson N (2012) Developments in rabies vaccines. Clin Exp Immunol 169:199–204. https://doi.org/10.1111/j.1365-2249.2012.04592.x
Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1–7. https://doi.org/10.1002/1521-4141(200001)30:1%3c1:AID-IMMU1%3e3.0.CO;2-%23
Hollevoet K, Declerck PJ (2017) State of play and clinical prospects of antibody gene transfer. J Transl Med 15:131. https://doi.org/10.1186/s12967-017-1234-4
Jacobson JM et al (2016) Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr 72:31–38. https://doi.org/10.1097/QAI.0000000000000926
Jagger BW et al (2019) Protective efficacy of nucleic acid vaccines against transmission of Zika virus during pregnancy in mice. J Infect Dis 220(10):1577–1588. https://doi.org/10.1093/infdis/jiz338
Joe PT et al (2019) Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice. J Transl Med 17:242. https://doi.org/10.1186/s12967-019-1991-3
Johansson DX, Ljungberg K, Kakoulidou M, Liljestrom P (2012) Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE 7:e29732. https://doi.org/10.1371/journal.pone.0029732
John S et al (2018) Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine 36:1689–1699. https://doi.org/10.1016/j.vaccine.2018.01.029
Kallen K-J et al (2013) A novel, disruptive vaccination technology. Hum Vaccin Immunother 9:2263–2276. https://doi.org/10.4161/hv.25181
Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12:967–977. https://doi.org/10.1038/nmat3765
Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165–175. https://doi.org/10.1016/j.immuni.2005.06.008
Kariko K et al (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16:1833–1840. https://doi.org/10.1038/mt.2008.200
Kariko K, Muramatsu H, Ludwig J, Weissman D (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39:e142. https://doi.org/10.1093/nar/gkr695
Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, Vossen A, de Melker HE (2017) Congenital cytomegalovirus infection: child development, quality of life and impact on daily life. Pediatr Infect Dis J 36:1141–1147. https://doi.org/10.1097/INF.0000000000001663
Kose N et al (2019) A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against Chikungunya infection. Sci Immunol 4(35):eaaw6647. https://doi.org/10.1126/sciimmunol.aaw6647
Kowalski PS, Rudra A, Miao L, Anderson DG (2019) Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther 27:710–728. https://doi.org/10.1016/j.ymthe.2019.02.012
Kreiter S et al (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70:9031–9040. https://doi.org/10.1158/0008-5472.CAN-10-0699
Kreiter S et al (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520:692–696. https://doi.org/10.1038/nature14426
Li M et al (2016) Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release 228:9–19. https://doi.org/10.1016/j.jconrel.2016.02.043
Li B, Zhang X, Dong Y (2019) Nanoscale platforms for messenger RNA delivery. Wiley Interdisc Rev Nanomed Nanobiotechnol 11(2):e1530
Lindgren G et al (2017) Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol 8:1539. https://doi.org/10.3389/fimmu.2017.01539
Liu MA (2019) A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines 7:37. https://doi.org/10.3390/vaccines7020037
Looker KJ, Garnett GP, Schmid GP (2008) An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86:805–812, A. https://doi.org/10.2471/blt.07.046128
Lorenzi JC et al (2010) Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol 10:77. https://doi.org/10.1186/1472-6750-10-77
Luo F et al (2017) Induction of protective immunity against toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP). Front Microbiol 8:605. https://doi.org/10.3389/fmicb.2017.00605
Lutz J et al (2017) Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2:29. https://doi.org/10.1038/s41541-017-0032-6
Martens TF, Remaut K, Demeester J, De Smedt SC, Braeckmans K (2014) Intracellular delivery of nanomaterials: how to catch endosomal escape in the act. Nano Today 9:344–364. https://doi.org/10.1016/j.nantod.2014.04.011
Martinon F et al (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23:1719–1722. https://doi.org/10.1002/eji.1830230749
Maruggi G et al (2017) Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35:361–368. https://doi.org/10.1016/j.vaccine.2016.11.040
Maruggi G, Zhang C, Li J, Ulmer JB, Yu D (2019) mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther 27:757–772. https://doi.org/10.1016/j.ymthe.2019.01.020
Maugeri M et al (2019) Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat Commun 10:4333. https://doi.org/10.1038/s41467-019-12275-6
Melo M et al (2019) Immunogenicity of RNA replicons encoding HIV env immunogens designed for self-assembly into nanoparticles. Mol Ther 27:2080–2090. https://doi.org/10.1016/j.ymthe.2019.08.007
Meyer M et al (2018) Modified vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J Infect Dis 217:451–455. https://doi.org/10.1093/infdis/jix592
Meyer M, Malherbe DC, Bukreyev A (2019) Can Ebola virus vaccines have universal immune correlates of protection? Trends Microbiol 27:8–16. https://doi.org/10.1016/j.tim.2018.08.008
Mohamed M et al (2019) PEGylated liposomes: immunological responses. Sci Technol Adv Mater 20:710–724. https://doi.org/10.1080/14686996.2019.1627174
Mooi FR, de Greeff SC (2007) The case for maternal vaccination against pertussis. Lancet Infect Dis 7:614–624. https://doi.org/10.1016/S1473-3099(07)70113-5
Moyo N et al (2019) Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA. Mol Ther Methods Clin Dev 12:32–46. https://doi.org/10.1016/j.omtm.2018.10.010
Paessler S, Weaver SC (2009) Vaccines for Venezuelan equine encephalitis. Vaccine 27(Suppl 4):D80–D85. https://doi.org/10.1016/j.vaccine.2009.07.095
Pardi N et al (2017a) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543:248–251. https://doi.org/10.1038/nature21428
Pardi N et al (2017b) Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun 8:14630. https://doi.org/10.1038/ncomms14630
Pardi N, Hogan MJ, Porter FW, Weissman D (2018a) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov 17:261–279. https://doi.org/10.1038/nrd.2017.243
Pardi N et al (2018b) Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun 9:3361. https://doi.org/10.1038/s41467-018-05482-0
Pardi N et al (2018c) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215:1571–1588. https://doi.org/10.1084/jem.20171450
Pardi N et al (2019) Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and Rhesus Macaques. Mol Ther Nucleic Acids 15:36–47. https://doi.org/10.1016/j.omtn.2019.03.003
Patel S et al (2017) Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA. Nano Lett 17:5711–5718. https://doi.org/10.1021/acs.nanolett.7b02664
Pepini T et al (2017) Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol 198(10):4012–4024. https://doi.org/10.4049/jimmunol.1601877
Petsch B et al (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30:1210–1216. https://doi.org/10.1038/nbt.2436
Plotkin SA, Plotkin SL (2011) The development of vaccines: how the past led to the future. Nat Rev Microbiol 9:889–893. https://doi.org/10.1038/nrmicro2668
Pollard C et al (2013) Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 21:251–259. https://doi.org/10.1038/mt.2012.202
Quiroz E, Moreno N, Peralta PH, Tesh RB (1988) A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg 39:312–314. https://doi.org/10.4269/ajtmh.1988.39.312
Rappuoli R, Bottomley MJ, D’Oro U, Finco O, Gregorio ED (2016) Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J Exp Med 213:469–481. https://doi.org/10.1084/jem.20151960
Rauch S, Lutz J, Kowalczyk A, Schlake T, Heidenreich R (2017) RNActive® technology: generation and testing of stable and immunogenic mRNA vaccines. Methods Mol Biol 89–107
Rauch S, Jasny E, Schmidt KE, Petsch B (2018) New vaccine technologies to combat outbreak situations. Front Immunol 9:1963. https://doi.org/10.3389/fimmu.2018.01963
Rehman Z, Zuhorn IS, Hoekstra D (2013) How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances. J Control Release 166:46–56. https://doi.org/10.1016/j.jconrel.2012.12.014
Richner JM et al (2017a) Modified mRNA vaccines protect against Zika virus infection. Cell 168:1114–1125 e1110. https://doi.org/10.1016/j.cell.2017.02.017
Richner JM et al (2017b) Vaccine mediated protection against Zika virus-induced congenital disease. Cell 170:273–283 e212. https://doi.org/10.1016/j.cell.2017.06.040
Richner JM, Diamond MS (2018) Zika virus vaccines: immune response, current status, and future challenges. Curr Opin Immunol 53:130–136. https://doi.org/10.1016/j.coi.2018.04.024
Roth C et al (2019) A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice. Front Immunol 10:1424. https://doi.org/10.3389/fimmu.2019.01424
Routy JP et al (2010) Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 134:140–147. https://doi.org/10.1016/j.clim.2009.09.009
Saadatnia G, Golkar M (2012) A review on human toxoplasmosis. Scand J Infect Dis 44:805–814. https://doi.org/10.3109/00365548.2012.693197
Sabnis S et al (2018) A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther 26:1509–1519. https://doi.org/10.1016/j.ymthe.2018.03.010
Sahay G, Alakhova DY, Kabanov AV (2010) Endocytosis of nanomedicines. J Control Release 145:182–195. https://doi.org/10.1016/j.jconrel.2010.01.036
Sahay G et al (2013) Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 31:653–658. https://doi.org/10.1038/nbt.2614
Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov 13:759–780. https://doi.org/10.1038/nrd4278
Samsa MM et al (2019) Self-amplifying RNA vaccines for Venezuelan equine Encephalitis virus induce robust protective immunogenicity in mice. Mol Ther 27:850–865. https://doi.org/10.1016/j.ymthe.2018.12.013
Scheel B et al (2004) Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 34:537–547. https://doi.org/10.1002/eji.200324198
Scheel B et al (2005) Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35:1557–1566. https://doi.org/10.1002/eji.200425656
Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (2012) Developing mRNA-vaccine technologies. RNA Biol 9:1319–1330. https://doi.org/10.4161/rna.22269
Schnee M et al (2016) An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis 10:e0004746. https://doi.org/10.1371/journal.pntd.0004746
Schroeder J, Aebischer T (2011) Vaccines for leishmaniasis: from proteome to vaccine candidates. Hum Vaccin 7(Suppl):10–15. https://doi.org/10.4161/hv.7.0.14556
Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG (2010) Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267:9–21. https://doi.org/10.1111/j.1365-2796.2009.02189.x
Scorza FB, Pardi N (2018) New kids on the block: RNA-based influenza virus vaccines. Vaccines (Basel) 6. https://doi.org/10.3390/vaccines6020020
Semple SC, Chonn A, Cullis PR (1998) Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv Drug Del Rev 32:3–17. https://doi.org/10.1016/S0169-409X(97)00128-2
Semple SC et al (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172–176. https://doi.org/10.1038/nbt.1602
Settembre EC, Dormitzer PR, Rappuoli R (2014) Bringing influenza vaccines into the 21st century. Hum Vaccin Immunother 10:600–604. https://doi.org/10.4161/hv.27600
Sohn RL et al (2001) In-vivo particle mediated delivery of mRNA to mammalian tissues: ballistic and biologic effects. Wound Repair Regen 9:287–296. https://doi.org/10.1046/j.1524-475X.2001.00287.x
Steitz J, Britten CM, Wolfel T, Tuting T (2006) Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 55:246–253. https://doi.org/10.1007/s00262-005-0042-5
Stitz L et al (2017) A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis 11:e0006108. https://doi.org/10.1371/journal.pntd.0006108
Szebeni J (2005) Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216:106–121. https://doi.org/10.1016/j.tox.2005.07.023
Szebeni J (2014) Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 61:163–173. https://doi.org/10.1016/j.molimm.2014.06.038
Szebeni J, Simberg D, González-Fernández Á, Barenholz Y, Dobrovolskaia MA (2018) Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotech 13:1100–1108. https://doi.org/10.1038/s41565-018-0273-1
Tabernero J et al (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3:406–417. https://doi.org/10.1158/2159-8290.CD-12-0429
Takahashi H, Sinoda K, Hatta I (1996) Effects of cholesterol on the lamellar and the inverted hexagonal phases of dielaidoylphosphatidylethanolamine. Biochim Biophys Acta 1289:209–216. https://doi.org/10.1016/0304-4165(95)00170-0
Tao W et al (2011) Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. Mol Ther 19:567–575. https://doi.org/10.1038/mt.2010.282
Taranejoo S, Liu J, Verma P, Hourigan K (2015) A review of the developments of characteristics of PEI derivatives for gene delivery applications. J Appl Polym Sci 132. https://doi.org/10.1002/app.42096
Telford JL (2008) Bacterial genome variability and its impact on vaccine design. Cell Host Microbe 3:408–416. https://doi.org/10.1016/j.chom.2008.05.004
Thess A et al (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23:1456–1464. https://doi.org/10.1038/mt.2015.103
Thran M et al (2017) mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med 9(10):1434–1447. https://doi.org/10.15252/emmm.201707678
Tiwari PM et al (2018) Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat Commun 9:3999. https://doi.org/10.1038/s41467-018-06508-3
Vaidyanathan S et al (2018) Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Ther Nucleic Acids 12:530–542. https://doi.org/10.1016/j.omtn.2018.06.010
Van Gulck E et al (2012) mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 26:F1–12. https://doi.org/10.1097/QAD.0b013e32834f33e8
Van Lint S et al (2012) Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72:1661–1671. https://doi.org/10.1158/0008-5472.CAN-11-2957
Van Lint S, Heirman C, Thielemans K, Breckpot K (2013) mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9:265–274. https://doi.org/10.4161/hv.22661
VanBlargan LA et al (2019) An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections. Cell Rep 25:3382–3392 e3383. https://doi.org/10.1016/j.celrep.2018.11.082
Vermeulen LMP et al (2018) Endosomal size and membrane leakiness influence proton sponge-based rupture of endosomal vesicles. ACS Nano 12:2332–2345. https://doi.org/10.1021/acsnano.7b07583
Voysey M et al (2017) The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: an individual participant meta-analysis. JAMA Pediatr 171:637–646. https://doi.org/10.1001/jamapediatrics.2017.0638
Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185:45–52
Walker LM et al (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466–470. https://doi.org/10.1038/nature10373
Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC (2004) Venezuelan equine encephalitis. Annu Rev Entomol 49:141–174. https://doi.org/10.1146/annurev.ento.49.061802.123422
Wei X et al (2003) Antibody neutralization and escape by HIV-1. Nature 422:307–312. https://doi.org/10.1038/nature01470
Willis E et al (2020) Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Sci Transl Med 12:eaav5701. https://doi.org/10.1126/scitranslmed.aav5701
Wittrup A et al (2015) Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol 33:870–876. https://doi.org/10.1038/nbt.3298
Wolff JA et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468
Wu NC et al (2017) A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog 13:e1006682. https://doi.org/10.1371/journal.ppat.1006682
Yates NL et al (2014) Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6:228ra239. https://doi.org/10.1126/scitranslmed.3007730
Yin H et al (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15:541–555. https://doi.org/10.1038/nrg3763
Yin H, Kauffman KJ, Anderson DG (2017) Delivery technologies for genome editing. Nat Rev Drug Discov 16:387–399. https://doi.org/10.1038/nrd.2016.280
Younger DS, Younger AP, Guttmacher S (2016) Childhood vaccination: implications for global and domestic public health. Neurol Clin 34:1035–1047. https://doi.org/10.1016/j.ncl.2016.05.004
Zhao M, Li M, Zhang Z, Gong T, Sun X (2016) Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Deliv 23:2596–2607. https://doi.org/10.3109/10717544.2015.1038856
Zhong Z et al (2019) Immunogenicity and protection efficacy of a naked self-replicating Zika virus vaccine. Vaccines (Basel) 7. https://doi.org/10.3390/vaccines7030096
Zost SJ et al (2017) Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci 114:12578–12583. https://doi.org/10.1073/pnas.1712377114
Acknowledgements
The authors thank Dr. Michael J. Hogan for critical reading and revision of the manuscript. N. P. was supported by the National Institute of Allergy and Infectious Diseases (1R01AI146101). Figure 1 was created with BioRender.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Alameh, MG., Weissman, D., Pardi, N. (2020). Messenger RNA-Based Vaccines Against Infectious Diseases. In: Yu, D., Petsch, B. (eds) mRNA Vaccines. Current Topics in Microbiology and Immunology, vol 440. Springer, Cham. https://doi.org/10.1007/82_2020_202
Download citation
DOI: https://doi.org/10.1007/82_2020_202
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-18069-9
Online ISBN: 978-3-031-18070-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)